Yasmina Noubia Abdiche PhD

Dr. Abdiche joined Carterra as CSO in 2016 after twelve and half years’ experience in the pharmaceutical industry at Rinat-Pfizer, where she was a Research Fellow, a member of Rinat’s leadership team, served on the governing committee for Pfizer’s Postdoctoral Program, and led a group of analytical scientists that applied label-free biosensors to the discovery of therapeutic antibodies. After graduating from Oxford University in the UK with a PhD in Biological Chemistry and a Master’s degree in Chemistry, Dr. Abdiche completed postdoctoral research in Dr. David Myszka’s laboratory at the University of Utah in Salt Lake City, where she optimized biosensor methods for characterizing small molecule interactions.
Dr. Abdiche is co-inventor of several therapeutic antibodies in clinical trials, including Teva’s fremanezumab (formerly TEV-48125, RN-307) an anti-CGRP antibody which successfully completed PhIII clinical trials for chronic migraine and is expected to achieve US market approval in 2018, bococizumab, a PCSK9 inhibitor that was tested in PhIII clinical trials for hypercholesteremia, and RN888, a PD-1 inhibitor currently in PhI clinical trials for cancer immunotherapy.